Nevro Corp. Expands Talent Pool with New Employee Inducement Grants

On January 21, 2025, Nevro Corp. (NYSE: NVRO), a leading global medical device organization, made headlines with its recent decision to issue new employee inducement grants. This move aligns with the company’s ongoing mission to transform the treatment of chronic pain. The grants, announced by Nevro’s Board of Directors, specifically the Compensation Committee, cover 21,026 shares of its common stock and aim to entice ten new non-executive employees to join the firm.

Details of the Inducement Grants

The inducement grants were awarded on January 7, 2025, under the Nevro Corp. 2023 Inducement Award Plan. Each award vests over a three-year period provided the employees remain with Nevro through each vesting date. This compensation strategy is not only a part of the attraction for new employees but also ensures that they are engaged for the long term as Nevro continues to innovate within the healthcare realm. In accordance with NYSE Listed Company Manual Rule 303A.08, these grants serve as a substantial inducement to potential employees in a competitive market that is increasingly focused on attracting top talent.

About Nevro Corp.

Headquartered in Redwood City, California, Nevro Corp. is renowned for delivering comprehensive and transformative solutions in the chronic pain treatment space. With a commitment to setting high standards for patient outcomes, the company has developed the proprietary 10 kHz Therapy™, a non-pharmacological treatment which has positively impacted over 115,000 patients worldwide.

Nevro’s advanced HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system, which is tailored to address chronic pain in both the trunk and limbs, as well as painful diabetic neuropathy. Furthermore, Nevro offers minimally invasive options for chronic sacroiliac joint (SI joint) pain and boasts a robust portfolio in the SI joint fusion space, aimed at improving patient outcomes while catering to varied physician and patient preferences.

Innovative Treatment Solutions

Nevro stands out in the medical device sector with its unique offerings, including the only SCS systems designed to implement the proprietary 10 kHz Therapy, such as the Senza®, Senza II®, Senza Omnia™, and HFX iQ. Furthermore, the company enhances the patient experience through dedicated support services, providing patients with an HFX Coach™ throughout their pain relief journey and doctors with Nevrocloud™ insights to facilitate superb patient management and practice oversight.

Commitment to Community and Innovation

Nevro’s recent inducement grant initiative highlights its dedication not only to innovation but also to building a strong community by attracting competent talents who share its vision and mission. The healthcare industry is under constant transformation, and Nevro’s commitment to hiring and maintaining skilled professionals demonstrates the company's resolve to keep pace with advancements in pain management therapies.

For more information about Nevro Corp. and to stay updated with the latest news, visit the company’s official website at nevro.com. Interested parties are encouraged to connect with Nevro on social media platforms, such as LinkedIn, X, Facebook, and Instagram, to further follow the advances in their groundbreaking therapies.

Conclusion

Through strategic inducement grants, Nevro Corp. is not only enhancing its capacity to innovate in the pain treatment sphere but also ensuring that it attracts talent who will contribute to its mission of improving the lives of individuals suffering from chronic pain. As Nevro continues to grow and adapt, this commitment puts them in an excellent position within the fiercely competitive medical technology industry.